

COMPUMED INC  
Form 8-K  
July 29, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 28, 2008**

**COMPUMED, INC.**

(Exact name of registrant as specified in its charter)

Edgar Filing: COMPUMED INC - Form 8-K

<b>DELAWARE</b>	<b>000-14210</b>	<b>95-2860434</b>
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

**5777 West Century Blvd., Suite 360, Los Angeles, CA, 90045**

(Address of Principal Executive Office) (Zip Code)

**(310) 258-5000**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**ITEM 7.01**

**REGULATION FD DISCLOSURE**

On July 28, 2008, CompuMed, Inc. ( the Company ) announced it has received approval from the State Food and Drug Administration (SFDA) of the People s Republic of China to market the OsteoGram system for screening, diagnosing and monitoring osteoporosis.

A copy of the press release is attached herein as Exhibit 99.1 to this Current Report on Form 8-K.

**ITEM 9.01**

**FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits

**EXHIBIT**

<b>NUMBER</b>	<b>DESCRIPTION</b>
<u>99.1</u>	CompuMed, Inv. announces approval to market the OsteoGram system for screening, diagnosing and monitoring osteoporosis.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CompuMed, Inc.**

(Registrant)

Date: July 29, 2008

By: /s/ Maurizio Vecchione

Name: Maurizio Vecchione

Title: Interim Chief Executive Officer